Obserwuj
Sergio A. Quezada
Sergio A. Quezada
UCL Cancer Institute
Zweryfikowany adres z ucl.ac.uk
Tytuł
Cytowane przez
Cytowane przez
Rok
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ...
Science 351 (6280), 1463-1469, 2016
31382016
Tracking the evolution of non–small-cell lung cancer
M Jamal-Hanjani, GA Wilson, N McGranahan, NJ Birkbak, TBK Watkins, ...
New England Journal of Medicine 376 (22), 2109-2121, 2017
23282017
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ...
Annals of Oncology 30 (1), 44-56, 2019
22492019
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ...
Nature 545 (7655), 446-451, 2017
18182017
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
TR Simpson, F Li, W Montalvo-Ortiz, MA Sepulveda, K Bergerhoff, F Arce, ...
Journal of Experimental Medicine 210 (9), 1695-1710, 2013
16592013
Cutting edge: contact-mediated suppression by CD4+ CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism
DC Gondek, LF Lu, SA Quezada, S Sakaguchi, RJ Noelle
The journal of immunology 174 (4), 1783-1786, 2005
13962005
Allele-specific HLA loss and immune escape in lung cancer evolution
N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ...
Cell 171 (6), 1259-1271. e11, 2017
12662017
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
KS Peggs, SA Quezada, CA Chambers, AJ Korman, JP Allison
Journal of Experimental Medicine 206 (8), 1717-1725, 2009
11382009
Cyclooxygenase-dependent tumor growth through evasion of immunity
S Zelenay, AG Van Der Veen, JP Böttcher, KJ Snelgrove, N Rogers, ...
Cell 162 (6), 1257-1270, 2015
10782015
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
SA Quezada, TR Simpson, KS Peggs, T Merghoub, J Vider, X Fan, ...
Journal of Experimental Medicine 207 (3), 637-650, 2010
10282010
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
S Turajlic, K Litchfield, H Xu, R Rosenthal, N McGranahan, JL Reading, ...
The lancet oncology 18 (8), 1009-1021, 2017
9152017
CD40/CD154 interactions at the interface of tolerance and immunity
SA Quezada, LZ Jarvinen, EF Lind, RJ Noelle
Annu. Rev. Immunol. 22 (1), 307-328, 2004
8882004
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
SA Quezada, KS Peggs, MA Curran, JP Allison
The Journal of clinical investigation 116 (7), 1935-1945, 2006
8152006
Neoantigen-directed immune escape in lung cancer evolution
R Rosenthal, EL Cadieux, R Salgado, MA Bakir, DA Moore, CT Hiley, ...
Nature 567 (7749), 479-485, 2019
8022019
Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
K Litchfield, JL Reading, C Puttick, K Thakkar, C Abbosh, R Bentham, ...
Cell 184 (3), 596-614. e14, 2021
6812021
Translational implications of tumor heterogeneity
M Jamal-Hanjani, SA Quezada, J Larkin, C Swanton
Clinical cancer research 21 (6), 1258-1266, 2015
5892015
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
KS Peggs, SA Quezada, AJ Korman, JP Allison
Current opinion in immunology 18 (2), 206-213, 2006
5862006
Fc effector function contributes to the activity of human anti-CTLA-4 antibodies
FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ...
Cancer cell 33 (4), 649-663. e4, 2018
5802018
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
B Philip, E Kokalaki, L Mekkaoui, S Thomas, K Straathof, B Flutter, ...
Blood, The Journal of the American Society of Hematology 124 (8), 1277-1287, 2014
4622014
Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors
FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ...
Immunity 46 (4), 577-586, 2017
4452017
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–20